Melanoma Is Up: Are We Up to This Challenge?

Melanoma in situ: Part I. Epidemiology, screening, and clinical features

The incidence of melanoma has steadily increased over the past 3 decades, with melanoma in situ comprising a disproportionately high percentage of the rising incidence. Our understanding of melanoma in situ has been shaped by epidemiologic and clinical studies. Central to a review of melanoma in situ is a focus on its epidemiology, pathology, biologic behavior, treatment, and clinical outcome, which may differ significantly from that of malignant melanoma. Part I of this continuing medical education article reviews the epidemiology, risk factors, and clinical features of melanoma in situ; part II covers the histopathology, treatment options, and clinical management.

Ambulatory melanoma care patterns in the United States

Objective. To examine trends in melanoma visits in the ambulatory care setting. Methods. Data from the National Ambulatory Medical Care Survey (NAMCS) from 1979 to 2010 were used to analyze melanoma visit characteristics including number of visits, age and gender of patients, and physician specialty. These data were compared to US Census population estimates during the same time period. Results. The overall rate of melanoma visits increased (P < 0.0001) at an apparently higher rate than the increase in population over this time. The age of patients with melanoma visits increased at approximately double the rate (0.47 year per interval year, P < 0.0001) of the population increase in age (0.23 year per interval year). There was a nonsignificant (P = 0.19) decline in the proportion of female patients seen over the study interval. Lastly, ambulatory care has shifted towards dermatologists and other specialties managing melanoma patients and away from family/internal medicine physicians and general/plastic surgeons. Conclusions. The number and age of melanoma visits has increased over time with respect to the overall population, mirroring the increase in melanoma incidence over the past three decades. These trends highlight the need for further studies regarding melanoma management efficiency.

Melanoma thickness trends in the United States, 1988-2006

Over the past two decades, numerous efforts have been initiated to improve screening and early detection of melanoma both in the United States and worldwide. It is commonly believed that these efforts have contributed to the stabilization of melanoma mortality, and that the proportion of thick melanoma with unfavorable prognosis is on the decline. Data obtained from 17 population-based cancer registries of the Surveillance Epidemiology and End Result (SEER) program of the National Cancer Institute for 1988-2006 were used to examine trends in melanoma tumor thickness. For malignant melanoma cases with recorded thickness, the proportionate distribution among four thickness categories (<or=1, 1.01-2, 2.01-4, and >4 mm) remained relatively stable over the 19-year study period, however, for melanomas resulting in death, the proportion of thick tumors increased. The most substantial change occurred in the proportion of melanoma in situ, which nearly doubled from 1988 to 2006. Surveillance and early detection efforts in the United States have not resulted in a substantial reduction in the proportion of tumors with prognostically unfavorable thickness. Continued improvement and new methods of screening, especially among demographics with higher incidence of thick tumors, is necessary.